

Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab

December 10, 2009

TARRYTOWN, N.Y., Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009. The presentation is scheduled for 3:35 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through January 15, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

Contact Information:

Peter Dworkin Laura Lindsay Investor Relations Media Relations 914.345.7640 914.345.7800

peter.dworkin@regeneron.com laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

http://www.regeneron.com

Copyright (C) 2009 PR Newswire. All rights reserved